



ZIOPHARM Oncology, Inc.
 Investor Relations Department
 One First Ave., Parris Building, # 34
 Navy Yard Plaza
 Boston, MA 02199
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: ZIOP

Last Trade:	6.07
Trade Time:	4:00 PM ET Jun 22, 2017
Change:	0.18 (+3.056%)
Day Range	5.91 - 6.24
52-Week Range	4.45 - 7.88
Volume	1,218,253


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 5, 2017 [ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Velelimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting](#)
- Jun 2, 2017 [ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 17, 2017 [ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Velelimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting](#)
- May 12, 2017 [ZIOPHARM Oncology Announces Pricing of \\$50 Million Follow-On Offering of Common Stock](#)
- May 2, 2017 [ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia](#)

Financials [\[View all \]](#)

- Feb 16, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 1, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 9, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 9, 2016 [Quarterly Report \(10-Q\)](#)